310 related articles for article (PubMed ID: 37020035)
1. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor efficacy of a potent and selective non-covalent KRAS
Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
5. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
6. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
8. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
9. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
[TBL] [Abstract][Full Text] [Related]
11. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
12. Inhibition mechanism of MRTX1133 on KRAS
Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
[TBL] [Abstract][Full Text] [Related]
13. KRAS inhibitors: going noncovalent.
Drosten M; Barbacid M
Mol Oncol; 2022 Dec; 16(22):3911-3915. PubMed ID: 36383067
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
15. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
[TBL] [Abstract][Full Text] [Related]
16. KRAS
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Paradiso F; Sugimoto H; Arian KA; Ying H; Barekatain Y; Sthanam LK; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
Cancer Cell; 2023 Sep; 41(9):1606-1620.e8. PubMed ID: 37625401
[TBL] [Abstract][Full Text] [Related]
17. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
Tarpgaard LS; Ørum-Madsen MS; Christensen IJ; Nordgaard C; Noer J; Guren TK; Glimelius B; Sorbye H; Ikdahl T; Kure EH; Tveit KM; Nielsen HJ; Pfeiffer P; Brünner N; Moreira JM
Oncotarget; 2016 Sep; 7(37):59441-59457. PubMed ID: 27509063
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
19. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
Kim S; Kim N; Kang K; Kim W; Won J; Cho J
Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
[TBL] [